NCCN Curtain Raiser

by | Apr 5, 2024 | LM

Visit our poster at the National Comprehensive Cancer Network® (NCCN®) conference today and say hello to our clinical team! The poster will be available on our website after the conference

CSF-01 Implementation

by | Mar 28, 2024 | LM

In case you missed it, we announced the validation & clinical implementation of our CSF-01 Leptomeningeal Cancer Cell Diagnostic. The CSF-01 cancer cell enumeration test is an exploratory endpoint in the ReSPECT-LM Phase 1 trial that has shown promise in the...

NCCN Curtain Raiser

by | Mar 27, 2024 | LM

❗Mark Your Calendars❗ Plus Therapeutics will be presenting a poster at the National Comprehensive Cancer Network Annual Conference Press release: https://bit.ly/PSTV_PR...

Susan G. Komen: LM

by | Mar 26, 2024 | LM

Thank you to @SusanGKomen for adding “Leptomeningeal Metastasis” to your Breast Cancer Glossary patient resource! 🎗️ “Leptomeningeal Metastasis: Cancer that spreads from the original tumor to the meninges (the thin layers of tissue that cover and...

CSF-01 Announcement

by | Mar 25, 2024 | LM

BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic > Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and...

LM Cohort 5 Completion

by | Mar 11, 2024 | LM

BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date. The trial is STILL ENROLLING and accepting new...